Abstract
Postoperative Delirium (POD) is the most common complication following surgery among older adults, and has been consistently associated with increased mortality and morbidity, cognitive decline, and loss of independence, as well as markedly increased health-care costs. The development of new tools to identify individuals at high risk for POD could guide clinical decision-making and enable targeted interventions to potentially decrease delirium incidence and POD-related complications. In this study, we used machine learning techniques to evaluate whether baseline (pre-operative) cognitive function and resting-state electroencephalography could be used to identify patients at risk for POD. Pre-operative resting-state EEGs and the Montreal Cognitive Assessment (MoCA) were collected from 85 patients (age = 73 ± 6.4 years) undergoing elective surgery, 12 of whom subsequently developed POD. The model with the highest f1-score for predicting delirium, a linear-discriminant analysis (LDA) model incorporating MoCA scores and occipital alpha-band EEG features, was subsequently validated in an independent, prospective cohort of 51 older adults (age ≥ 60) undergoing elective surgery, 6 of whom developed POD. The LDA-based model, with a total of 7 features, was able to predict POD with area under the receiver operating characteristic curve, specificity and accuracy all >90%, and sensitivity > 80%, in the validation cohort. Notably, models incorporating both resting-state EEG and MoCA scores outperformed those including either EEG or MoCA alone. While requiring prospective validation in larger cohorts, these results suggest that prediction of POD with high accuracy may be feasible in clinical settings using simple and widely available clinical tools.
Highlights
Predict postoperative delirium using pre-operative EEG alpha power and MoCA scores.
Prediction performance improves over cognitive assessment alone.
ROC-AUC, specificity, accuracy >90%, and sensitivity > 80%, in a validation cohort.
Abnormalities in baseline EEG are a risk factor for postoperative delirium.
Competing Interest Statement
Dr. E. Santarnecchi serves on the scientific advisory boards for BottNeuro, which has no overlap with present work; and is listed as an inventor on several issued and pending patents on brain stimulation solutions to diagnose or treat neurodegenerative disorders and brain tumors. Dr. A. Pascual-Leone is a co-founder of Linus Health and TI Solutions AG which have no overlap with present work. He serves on the scientific advisory boards for the ACE Foundation and the IT'IS Foundation, Neuroelectrics, TetraNeuron, Skin2Neuron, MedRhythms, and Magstim Inc; and is listed as an inventor on several issued and pending patents on the real-time integration of noninvasive brain stimulation with electroencephalography and magnetic resonance imaging, applications of noninvasive brain stimulation in various neurological disorders, as well as digital biomarkers of cognition and digital assessments for early diagnosis of dementia. Dr. M Berger has received private legal consulting fees related to perioperative neurocognitive disorders. None of the other authors report any conflicts of interest. All the other co-authors fully disclose they have no financial interests, activities, relationships and affiliations. The other co-authors also declare they have no potential conflicts in the three years prior to submission of this manuscript.
Funding Statement
This manuscript was funded by grants P01AG031720 (SKI), R33AG071744 (SKI/RNJ), K76-AG057022 (MB), R01- AG073598 (MB), UH2-AG056925 (HEW, CCE) and a NIDUS pilot grant to MMS, MB and BW from R24-AG054259 (SKI). Dr. Ross was supported during manuscript preparation by the Department of Veterans Affairs Office of Academic Affiliations Advanced Fellowship Program in Mental Illness Research and Treatment, the Medical Research Service of the Veterans Affairs Palo Alto Health Care System and the Department of Veterans Affairs Sierra-Pacific Data Science Fellowship. Dr. Santarnecchi was partially supported by the NIH (P01 AG031720,) and ADDF (ADDF-FTD GA201902-2017902). Dr. Inouye holds the Milton and Shirley F. Levy Family Chair at Hebrew SeniorLife/Harvard Medical School, and is supported in part by grants P01AG031720 and R33AG071744 from the National Institutes of Health. She is the Editor in Chief of JAMA Internal Medicine. Dr. Shafi was partly supported by the Football Players Health Study at Harvard University, and the National Institutes of Health (R01MH115949, R01AG060987, and P01 AG031720.) Dr. A. Pascual-Leone was partly supported by the National Institutes of Health (R01AG076708, R01AG059089, R03AG072233, and P01 AG031720), the Bright Focus Foundation, and the Barcelona Brain Health Initiative (Institute Guttmann). Dr. Marcantonio was partially supported by the following grants from the National Institute on Aging (P01 AG031720, R01AG051658, K24 AG035075. Dr. Berger was partially supported by the National Institutes of Health K76AG057022 and R01AG073598, and received additional supports from the National Institutes of Health (P30-AG028716, P30-AG072958 and UH2-AG056925).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The institutional review boards of Beth Israel Deaconess Medical Center, Brigham and Women's Hospital, the Brigham and Women's Faulkner Hospital, and Duke University Health System - the study hospitals, and Hebrew SeniorLife - the study coordinating center, gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
